| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.0 | 21.8 |
| Net income | -8.0 | -8.7 |
| EPS (diluted, $ a share) | $-0.75 | $-1.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.4% |
|---|---|
| Operating margin | -25.4% |
10-Q filed with the SEC, NASDAQ: BDSX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biodesix Inc: key numbers
- Share price
- $9.00Close, Nov 16
- Market cap
- $99.8M
- Shares outstanding
- 11.09MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biodesix Inc
All →Biodesix 10% Owner Jack W. Schuler Buys $1M of Stock
Jack W. Schuler, 10% Owner, bought 100,000 shares of Biodesix Inc at $10.02 a share, worth $1M in total on Nov 10, 2026. Shares held after the trade: 655,810 (+18.0%).
- Value
- $1M
- Shares
- 100,000
- Price
- $10.02
- Role
- 10% Owner
- Holding change
- +18.0%
- Trade date
- Nov 10, 2026
Biodesix Leadership Change
Kieran O’Kane, the Chief Commercial Officer of Biodesix, Inc., departed the company effective November 2, 2026. He will be eligible for separation benefits under his existing Executive Severance and Change in Control Agreement as a result of his qualifying termination.
Biodesix Financial Results
Biodesix reported Q3 2026 total revenue of $24.0 million, a 10% year-over-year increase driven by a 16% rise in Diagnostic Testing revenue. Despite the growth, the company revised its full-year 2026 revenue guidance downward to $101-$103 million, citing slower-than-expected sales representative contributions and seasonality.
- Term
- Q3 2026
“Biodesix delivered another quarter of year-over-year growth, with total revenue increasing 10%, Diagnostic Testing revenue increasing 16%, test volumes increasing 24%, and gross margin remaining strong at 81%. However, our growth was below our expectations, and we understand the principal drivers: fewer contributing sales representatives than planned limited new physician and account growth; greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers; and delays in external customer dependencies postponed the start of Development Services projects and the associated revenue recognition.”
Scott Hutton, Chief Executive Officer
“The factors that impacted the quarter were largely execution and timing related rather than a change in demand, clinical utility, or market opportunity. We have identified the drivers, taken corrective actions, and entered the fourth quarter with a larger sales organization positioned for improved execution.”
Scott Hutton, Chief Executive Officer